BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 30539847)

  • 21. Programmed Cell Death Ligand-1 (PDL-1) Correlates With Tumor Infiltration by Immune Cells and Represents a Promising Target for Immunotherapy in Endometrial Cancer.
    Hecking T; Thiesler T; Halbe J; Otten L; Recker F; Gevensleben H; Müller T; Schiller C; Egger EK; Fimmers R; Stope MB; Kristiansen G; Mustea A
    Anticancer Res; 2022 Mar; 42(3):1367-1376. PubMed ID: 35220229
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic implications of epithelial to mesenchymal transition related proteins (E-cadherin, Snail) and hypoxia inducible factor 1α in endometrioid endometrial carcinoma.
    Abouhashem NS; Ibrahim DA; Mohamed AM
    Ann Diagn Pathol; 2016 Jun; 22():1-11. PubMed ID: 27180053
    [TBL] [Abstract][Full Text] [Related]  

  • 23. MMR deficient undifferentiated/dedifferentiated endometrial carcinomas showing significant programmed death ligand-1 expression (sp 142) with potential therapeutic implications.
    Hacking S; Jin C; Komforti M; Liang S; Nasim M
    Pathol Res Pract; 2019 Oct; 215(10):152552. PubMed ID: 31353229
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hypoxia-inducible factor 1 alpha is essential for hypoxic p27 induction in endometrioid endometrial carcinoma.
    Horrée N; Gort EH; van der Groep P; Heintz AP; Vooijs M; van Diest PJ
    J Pathol; 2008 Jan; 214(1):38-45. PubMed ID: 17985331
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic significance of programmed death-1 and programmed death-ligand 1 expression in patients with esophageal squamous cell carcinoma.
    Chen K; Cheng G; Zhang F; Zhang N; Li D; Jin J; Wu J; Ying L; Mao W; Su D
    Oncotarget; 2016 May; 7(21):30772-80. PubMed ID: 27120796
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunohistochemical expression of PD-L1 and its correlation with microsatellite status in endometrial and ovarian clear cell carcinomas: a cross-sectional study.
    Ghasemi D; Ameli F; Nili F; Edjtemaei R; Sheikhhasani S
    BMC Cancer; 2022 Dec; 22(1):1362. PubMed ID: 36581850
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Necrosis related HIF-1alpha expression predicts prognosis in patients with endometrioid endometrial carcinoma.
    Seeber LM; Horrée N; van der Groep P; van der Wall E; Verheijen RH; van Diest PJ
    BMC Cancer; 2010 Jun; 10():307. PubMed ID: 20565904
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic significance of erythropoietin expression in human endometrial carcinoma.
    Acs G; Xu X; Chu C; Acs P; Verma A
    Cancer; 2004 Jun; 100(11):2376-86. PubMed ID: 15160341
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PD-L1 Immunohistochemical Expression in Endometrial Carcinoma: Egyptian Cross-Sectional Study.
    Wahba MG; Soliman SS; Salama ME; Nasr S; Al Shereef ZAE
    Asian Pac J Cancer Prev; 2024 Apr; 25(4):1441-1450. PubMed ID: 38680006
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PD-L1 and CD4 are independent prognostic factors for overall survival in endometrial carcinomas.
    Zhang S; Minaguchi T; Xu C; Qi N; Itagaki H; Shikama A; Tasaka N; Akiyama A; Sakurai M; Ochi H; Satoh T
    BMC Cancer; 2020 Feb; 20(1):127. PubMed ID: 32066405
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tumor immunity is related to
    Imai H; Kaira K; Hashimoto K; Nitanda H; Taguchi R; Yanagihara A; Umesaki T; Yamaguchi O; Mouri A; Kawasaki T; Yasuda M; Kobayashi K; Sakaguchi H; Kuji I; Kagamu H
    Cancer Med; 2021 Sep; 10(18):6317-6326. PubMed ID: 34363337
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Levels of hypoxia-inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma.
    Bos R; van der Groep P; Greijer AE; Shvarts A; Meijer S; Pinedo HM; Semenza GL; van Diest PJ; van der Wall E
    Cancer; 2003 Mar; 97(6):1573-81. PubMed ID: 12627523
    [TBL] [Abstract][Full Text] [Related]  

  • 33. B7-1 and programmed cell death-ligand 1 in primary and lymph node metastasis lesions of non-small cell lung carcinoma.
    Yamada T; Miki Y; Suzuki M; Kondoh O; Saito-Koyama R; Ono K; Okada Y; Sasano H
    Cancer Med; 2022 Jan; 11(2):479-491. PubMed ID: 34907653
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reduction of HIF-1α/PD-L1 by Catalytic Topoisomerase Inhibitor Induces Cell Death Through Caspase Activation in Cancer Cells Under Hypoxia.
    Miyata S; Ishii T; Kitanaka S
    Anticancer Res; 2024 Jan; 44(1):49-59. PubMed ID: 38159998
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic value of hypoxia-inducible factor-1 alpha and prolyl 4-hydroxylase beta polypeptide overexpression in gastric cancer.
    Zhang J; Wu Y; Lin YH; Guo S; Ning PF; Zheng ZC; Wang Y; Zhao Y
    World J Gastroenterol; 2018 Jun; 24(22):2381-2391. PubMed ID: 29904245
    [TBL] [Abstract][Full Text] [Related]  

  • 36. EZH2 regulates PD-L1 expression via HIF-1α in non-small cell lung cancer cells.
    Zhao Y; Wang XX; Wu W; Long H; Huang J; Wang Z; Li T; Tang S; Zhu B; Chen D
    Biochem Biophys Res Commun; 2019 Sep; 517(2):201-209. PubMed ID: 31331645
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PD-L1 Regulates Inflammation in LPS-Induced Lung Epithelial Cells and Vascular Endothelial Cells by Interacting with the HIF-1α Signaling Pathway.
    Zhao S; Gao J; Li J; Wang S; Yuan C; Liu Q
    Inflammation; 2021 Oct; 44(5):1969-1981. PubMed ID: 34014492
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HUVECs affect HuT-78 cell apoptosis and cytokine production via the HIF-1α-PD-L1/PD-1 pathway under hypoxia.
    Qiang L; Hong L; Jian X; Zhanlin Z
    Int Immunopharmacol; 2023 May; 118():110010. PubMed ID: 36924563
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Decursin promotes HIF-1α proteasomal degradation and immune responses in hypoxic tumour microenvironment.
    Ge Y; Yoon SH; Jang H; Jeong JH; Lee YM
    Phytomedicine; 2020 Nov; 78():153318. PubMed ID: 32896707
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PD-L1/PD-1 Expression in Endometrial Clear Cell Carcinoma: A Potential Surrogate Marker for Clinical Trials.
    Jin C; Hacking S; Liang S; Nasim M
    Int J Surg Pathol; 2020 Feb; 28(1):31-37. PubMed ID: 31311367
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.